title: [Gene therapy of cardiovascular disorders].
abstract: More than 300 protocols have been developed for human gene therapy, but, it has not yet been proved to be a successful therapeutic strategy. One of the most important barriers to success is the development of efficient gene delivery systems. We have developed HVJ-liposomes by combining fusion proteins of HVJ (Hemagglutinating virus of Japan; Sendai virus) with liposomes containing DNA. This vector system has been very effective for in vivo gene delivery, especially in cardiovascular systems. Using HVJ-liposomes, we have reported successful gene therapy experiments such as prevention of restenosis after balloon injury, suppression of dysfunction of vein graft, and experimental ischemic disorders. Indeed, the success in the treatment of arteriosclerosis obliterance by VEGF (vascular endothelial growth factor) gene transfer was reported recently. These cardiovascular gene therapy strategies appear to be very promising therapeutics in future.
authors.affiliation: Division of Gene Therapy Science, Osaka University, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Kaneda
authors.forename: R
authors.initials: R
authors.lastname: Morishita
mesh_terms: D002318:Cardiovascular Diseases / Q000628:therapy*; D001026:Coronary Artery Bypass; D004279:DNA, Viral; D016228:Endothelial Growth Factors / Q000235:genetics; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors; D006801:Humans; D008081:Liposomes; D008222:Lymphokines / Q000235:genetics; D016376:Oligonucleotides, Antisense; D018108:Respirovirus; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: D004279:DNA, Viral; D016228:Endothelial Growth Factors; D008081:Liposomes; D008222:Lymphokines; D016376:Oligonucleotides, Antisense; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors